Loading
Nuvation Bio Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wentworth Kerry, was filed 18 Jun 2025.
Insider Decl.
120
Thresholds
n/a
Buy Volume
€28M
40 ops. · all time
Sell Volume
€64M
24 ops. · all time
Who traded when
BuySaleDongfang Liu8 sales
Gary Hattersley4 sales
Kerry Wentworth2 buys2 sales
Hung David3 buys
Mashal Robert2 buys
Philippe Sauvage2 buys
+4 other insiders
Since the insiders bought
- +192.4%Entry US$1.97 · Close at T+365 US$5.76
- +192.4%Entry US$1.97 · Close at T+365 US$5.76
- +192.4%Entry US$1.97 · Close at T+365 US$5.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Nuvation Bio Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$13.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,326 of 26,248 companies
32.7
score / 100
Value15
Quality50
FCF yld-11%
Earn yld-12%
EV/EBITDA·
ROE-48%
Gross mgn85%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.77
Analyst consensus
11 analystsStrong buy
US$7.00Target US$13.00(+173%)US$21.00
Income statement
RevenueUS$62.9M
Gross profitUS$53.6M85% margin
EBITDA-US$189.2M-301% margin
Net income-US$204.6M-88.2% margin
Valuation
PER (forward)-318.0x
P/Book6.6x
Beta1.62
Balance sheet & cash
Market capUS$1.7B
Total debtUS$57.4M
Free Cash Flow-US$181.8M
Debt / Equity164%
Profitability & ownership
ROE-47.8%
ROA-12.4%
% insiders17.2%
% institutions67.8%
Last declaration on 21 August 2026
Declarations120 total
100,000 shares@ US$1.870.0092% mcap15.7% of flowClass A Common StockSEC:0001521111-26-000005:0
100,000 shares@ US$7.09240.035% mcap59.6% of flowClass A Common StockSEC:0001521111-26-000005:1
100,000 shares@ US$6.960.034% mcap100.0% of flowCOMMONSEC144:0001950047-26-008412
39,999 shares@ US$2.170.0043% mcap93.5% of flowClass A Common StockSEC:0002039891-26-000008:0
1 shares@ US$1.970.0000% mcap0.0% of flowClass A Common StockSEC:0002039891-26-000008:1
47,668 shares@ US$5.760.014% mcap100.0% of flowCOMMONSEC144:0001950047-26-006424
125,000 shares@ US$5.760.036% mcap100.0% of flowCommonSEC144:0001950047-26-006426
63,000 shares@ US$5.760.018% mcap100.0% of flowCOMMONSEC144:0001950047-26-006425
50,000 shares@ US$5.020.012% mcap26.7% of flowClass A Common StockSEC:0001937915-26-000004:1
36,750 shares@ US$2.930.0053% mcap6.5% of flowClass A Common StockSEC:0001369453-26-000006:0
36,750 shares@ US$5.01440.0092% mcap11.2% of flowClass A Common StockSEC:0001369453-26-000006:1
50,000 shares@ US$1.940.0048% mcap10.3% of flowClass A Common StockSEC:0001937915-26-000004:0
100,000 shares@ US$1.9412.0% of flowClass A Common StockSEC:0001369453-26-000005:1
200,000 shares@ US$4.517855.9% of flowClass A Common StockSEC:0001369453-26-000005:2
100,000 shares@ US$1.8711.6% of flowClass A Common StockSEC:0001369453-26-000005:0
50,761 shares0Class A Common StockSEC:0002001938-26-000004:0
150,000 shares@ US$7.8244.1% of flowClass A Common StockSEC:0001937915-25-000010:1
150,000 shares@ US$2.9347.6% of flowClass A Common StockSEC:0001937915-25-000010:0
10,000 shares@ US$7.502.8% of flowClass A Common StockSEC:0001937915-25-000008:1
10,000 shares@ US$3.611.4% of flowClass A Common StockSEC:0001937915-25-000008:2
10,000 shares@ US$8.003.0% of flowClass A Common StockSEC:0001937915-25-000008:3
10,000 shares@ US$3.613.9% of flowClass A Common StockSEC:0001937915-25-000008:0
69,051 shares@ US$7.2310.1% of flowClass A Common StockSEC:0001521111-25-000006:1
300,000 shares@ US$1.9411.8% of flowClass A Common StockSEC:0001521111-25-000006:2
300,000 shares@ US$7.2344.0% of flowClass A Common StockSEC:0001521111-25-000006:3
25 of 120 declarations
About Nuvation Bio Inc.
At Nuvation Bio Inc., a US healthcare company valued at USD 1.7 billion, Oleg Nodelman, Director, signs the two largest purchases: EUR 6,057,364 on February 19, 2023 and EUR 6,048,125 on September 19, 2023; EcoR1 Panacea Holdings, LLC (Director) also bought for EUR 3,447,405 on July 6, 2020. From June 16, 2025 to June 18, 2025, 5 filers bought for EUR 955,783. In all, 40 purchases weigh EUR 28.1 million (median EUR 156,763).
Sales are fewer but much heavier: 24 worth EUR 64.0 million (median EUR 432,085), while purchases are 63% by count. The three largest come from Omega Fund V, L.P.: EUR 15,976,600 on November 3, 2021, EUR 12,836,461 on April 5, 2022 and EUR 12,155,920 on December 7, 2021.
Read moreShow less
The record gathers 120 filings from 28 filers between July 6, 2020 and August 21, 2026, including 24 option exercises and 20 grants. The annual volume is 38 in 2021, 7 in 2023, 33 in 2025 and 16 in 2026. The last twelve months hold 36, of which 14 sales and no purchase. Filers hold 17.2% of the capital. For 39 purchases, the stored 90-day result has a median of 1.3%, with 51% positive outcomes (stored past results, not a forecast).
